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Rotaviruses—non-enveloped,  double-stranded  RNA 
viruses—infect both humans and animals and are 
distributed worldwide. In humans, rotavirus causes 
diarrhoea of varying severity ranging from mild to 
severe. Symptoms, such as diarrhoea, vomiting, 
and fever, begin after an incubation period of 2-3 
days and persist, on average, for six days (1). Ro-
tavirus is the leading cause of severe diarrhoea in 
infants and young children, accounting for 45% of 
severe diarrhoeal disease in both developed and de-
veloping countries (2,3), responsible for ~5% of all 
deaths and 16% of potentially vaccine-preventable 
deaths among children globally (2,4). Rotaviruses 
are associated with 55% of all diarrhoea-related 
hospitalizations among children aged less than five 
years as revealed in the reports of the Asian Rotavi-
rus Surveillance Network (5). Virtually, all children 
throughout the world are infected with rotavirus 
by the time they are 3-5 years old, regardless of the 
socioeconomic status or environmental conditions 
(2,6).
The World Health Organization has recently esti-
mated that 611,000 (range 454,000-705,000) 
deaths due to rotavirus occur in children aged less 
than five years, accounting for approximately 20-
25% of all deaths due to diarrhoeal disease (7). 
Of the deaths due to rotavirus occurring worldwide, 
it is estimated that approximately 145,000 deaths 
occur  in  sub-Saharan  Africa  and  approximately 
200,000 deaths occur in Asia (8-10).
Studies have shown that rotavirus-associated dis-
ease occurs round the year in tropical climates 
with no consistent seasonal variation, although 
there may be more peaks in the dry, cool months, 
or winter months (11). Serotype G1, G2, G3, and 
G4 are responsible for 88% of gastroenteritis due 
to rotavirus, worldwide (12). These serotypes also 
account for over 80% of strains in Africa and over 
90% of strains in Asia. Other G serotypes that have 
become more common over the last decade include 
G9 (globally) and G8 (in Africa). Unusual G and P 
type combinations have been identified in Africa 
with an increasing frequency (13).
Safe and effective rotavirus vaccines are needed 
to reduce the enormous public-health burden as-
sociated with illness due to rotavirus, especially in 
developing countries (14). The large global burden 
of healthcare due to rotavirus-associated disease in 
both developed and developing countries prompt-
ed the development of rotavirus vaccines. Preven-
tion by vaccination is considered to be critical for 
effective control of infection due to rotavirus since 
it cannot be prevented with improvements in water 
and sanitation (11), and only non-specific symp-
tomatic therapies are available. Various approaches 
to the development of rotavirus vaccines have been 
undertaken, with live-attenuated oral vaccines re-
ceiving the most attention.
The first licensed rotavirus vaccine—RotaShield—a 
tetravalent rhesus rotavirus vaccine was manufac-
tured by Wyeth-Lederle and was licensed in the USA 
in 1998, and marketing authorization was granted 
for Europe in 1999 but was withdrawn from the 
market in 1999 due to an increased risk of intussus-
ception shortly after its administration (15,16). Un-
anticipated adverse events (intussusception) experi-
enced with the RotaSheild vaccine have accelerated 
efforts to develop and evaluate alternative vaccine 
candidates so that a safe and effective public-health 
tool would become available. Two new rotavirus 
vaccines—Rotarix by GSK and Rotateq by Merck—
have been developed. Both the vaccines were tested 
in both industrialized and middle-income countries 
among more than 60,000 infants which demonstrat-
ed its safety and efficacy. The vaccine had an efficacy 
of 85-98% against severe rotavirus-associated disease 
requiring hospitalization and reduced all-cause hos-
pitalizations by 42-59%, preventing nearly all hos-
pitalizations for rotavirus (17,18). Both the vaccines 
did not interfere with the immunogenicity when 
co-administered with other EPI vaccines, including 
polio (19-21). The vaccines were not associated with 
an increased risk of intussusception.
This issue of the Journal includes an article by Cons-
tenla et al. who evaluated the cost-effectiveness of a 
national rotavirus-vaccination progrmme in Brazil-
ian children (22). The authors developed a model 
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to estimate the disease outcomes and healthcare 
costs associated with diarrhoea due to rotavirus in 
a hypothetical annual birth-cohort of children for 
a five-year period. It has been estimated that rotavi-
rus vaccination in Brazil would prevent more than 
three-fourths of outpatient visits, hospitalizations, 
and deaths. The authors conclude that the rotavi-
rus-vaccination programme would be cost-effective 
and would provide an effective opportunity for im-
proving child health in Brazil.  
Further analyses were done to estimate the eco-
nomic burden and cost-effectiveness of rotavirus 
vaccination in Asia. The universal vaccination pro-
gramme in Asia would also reduce a substantial 
proportion of the burden of rotavirus-associated   
disease and related healthcare costs in Asia (23). 
They estimated reduction of 109,000 deaths (64%), 
1.4 million hospitalizations (74%), 7.7 million out-
patient visits (57%), and US$ 139 million (73%) 
in healthcare costs.
Both the vaccines—Rotarix and Rotateq—were ap-
proved by the FDA, and the vaccines have been 
licensed  in  many  countries.  Different  countries 
have already adopted the rotavirus vaccine in their 
routine EPI programme. Post-licensure monitoring 
of the burden of rotavirus-associated disease, safety 
of vaccine, and determination of circulating rotavi-
rus strains are needed. However, several challenges 
remain before the widespread use of rotavirus vac-
cines in developing countries. These include price-
related issues, awareness of diseases due to rotavi-
rus, and acceptance of the vaccine (24,25). 
There are concerns about the efficacy of rotavirus 
vaccine in developing countries since live oral en-
teric vaccines (polio, rotavirus) have been shown 
to be less immunogenic compared to developed 
countries (26,27; Steele AD. Personal communica-
tion, 2008). Further research would be helpful to 
determine the safety and efficacy of the vaccines, 
particularly among children in developing coun-
tries with a high prevalence of malnutrition, wide-
spread circulation of intestinal micro-organisms, 
and accompanying diseases, such as malaria and 
HIV. The demonstration of immune responses in 
presence of high maternal antibodies and breast-
feeding at the time of vaccination is important. 
The results of the ongoing rotavirus efficacy tri-
als in Asia (Bangladesh and Viet Nam) and Africa 
(Kenya, Ghana, and Mali) would provide informa-
tion whether the vaccine works well in developing 
countries. The rotavirus-effectiveness study which 
has just been started in Bangladesh will provide ex-
perience with the vaccine in a ‘real-world’ setting, 
and lessons will be learnt on vaccine delivery in the 
villages of Bangladesh. This would be helpful for 
the health ministry to decide to include the vac-
cine in its EPI programme for a rapid scale-up.  
The inclusion of rotavirus vaccine in the routine 
childhood-immunization programme in develop-
ing countries will help achieve the Millennium De-
velopment Goal of reducing childhood mortality 
through prevention of deaths due to rotavirus-asso-
ciated diseases (28).
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